Benign Prostatic Hyperplasia (BPH) Treatment Market 2022 Industry Size, Share, Growth, Outlook, Segmentation, Comprehensive Analysis by 2030

SDKI Inc. published a new report, "Benign Prostatic Hyperplasia (BPH) Treatment Market-Global Forecast 2026,". This study includes the statistical and analytical approaches needed to grow the BPH treatment market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-112016

The global benign prostatic hyperplasia treatment market is estimated to reach US $ 14.1 billion by 2026 from US $ 10.8 billion in 2021 and is projected to grow at a CAGR of 5.3% between 2021 and 2026. Growth in this market is driven by increased prevalence of benign prostatic hyperplasia, increased preference for minimally invasive surgery, increased obesity rates, and investment, funding and funding for research in the area of ​​BPH treatment

. I am. Emerging markets and promising product pipelines are also expected to provide opportunities for market growth during the forecast period.

Market segment
The BPH treatment market is by type [drugs (alpha blockers (tamsulosin, doxazosin), 5-alpha reductase inhibitors (finasteride, dutasteride), surgical treatments (TURP, TUMT, TUNA]], by end user (hospital). And by region. These segments are further subsegmented based on various factors, with some additions to the market such as the combined annual growth rate of each segment and subsegment, market value and volume during the valuation period. Consists of information.

The drug treatment segment is expected to hold the largest share of the benign prostatic hyperplasia treatment market in 2021.

Based on type, the BPH treatment market will be divided into drug and surgical treatments. The drug treatment segment is the largest and fastest growing segment in the market. It is primarily for the use of drug therapy as the primary treatment for men suffering from mild to moderate symptoms of BPH. The home care segment

is expected to hold the largest share of the benign prostatic hyperplasia treatment market by the end of 2021.

Based on the end user, the market is divided into home care and hospitals / clinics. In 2019, the home care segment accounted for the largest share of this market, as most patients are prescribed medication rather than surgery. Patients are also advised to continue taking the drug for weeks after surgery and may require a catheter for several days. Therefore, it is expected to drive the growth of this segment.

Report sample URL
https://www.sdki.jp/sample-request-112016

Regional Overview
The BPH treatment market is further subdivided based on the region, and the market growth of each country is evaluated. These include North America (US, Canada, and other North America), Europe (Germany, France, Italy, Spain, UK, and other Europe), Asia Pacific (China, Japan, India, Australia, and other Asia Pacific). ) And other regions.

In 2019, North America held the largest share of the benign prostatic hyperplasia treatment market. The large share of the region may be due to the growing population of the elderly and obese, and the availability of research funding. Key player initiatives are also expected to contribute to market growth.

About the detailed contents of the survey report
https://www.sdki.jp/reports/benign-prostatic-hyperplasia-treatment-market/112016

Key Players on the Market

The key players on the BPH treatment market are GlaxoSmithKline plc. (UK), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Eli Lilly and Company (US). , Teleflex Incorporated (USA) and more.

The study includes a detailed competitive analysis of these major companies in the BPH treatment market , corporate profiles, recent developments, and key market strategies.

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.